Clinical Trial Update: A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers [Phase 2]

View source ↗

Summary

Phase 2 study of Vemurafenib in participants with BRAF V600 mutation–positive cancers, including multiple myeloma and other neoplasms; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Neoplasms

Drugs mentioned

• Vemurafenib (vemurafenib)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Multiple Myeloma, Neoplasms | Phase 2 | Status: COMPLETED | Results posted: 2017-11-20